Safety and Efficacy of Linagliptin and Basal Insulin Combination Therapy in Elderly Patients (age ≥70 years) with Type 2 Diabetes (T2D)

被引：0

作者：

Woerle, H. J. ^{[1
]}

Neubacher, D. ^{[2
]}

Patel, S. ^{[3
]}

von Eynatten, M. ^{[1
]}

机构：

[1] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany

[2] Boehringer Ingelheim GmbH & Co KG, Biberach, Germany

[3] Boehringer Ingelheim GmbH & Co KG, Bracknell, Berks, England

来源：

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY | 2013年 / 61卷

关键词：

D O I：

暂无

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

引用

页码：S31 / S32

页数：2

共 50 条

[41] Efficacy and Safety of Linagliptin in General Surgical Patients with Type 2 Diabetes: Linagliptin Surgery Trial
Vellanki, Priyathama
Alexanian, Sara
Baldwin, David
Rasouli, Neda
Anzola, Isabel A.
Ramos, Clementina
Urrutia, Maria A.
Jones, Jocelyn
Modzelewski, Katherine
Ensminger, Elizabeth
Bakhtiari, Hoda F.
Pasquel, Francisco
Fayfman, Maya
Haw, Sonya
Peng, Limin
Umpierrez, Guillermo E.
DIABETES, 2017, 66 : A336 - A336
[42] A comparison of prandial premixed (ILPS/lispro) vs basal bolus (glargine/lispro) insulin therapy in obese patients with type 2 diabetes (T2D)
Ahmann, Andrew
Jiang, Honghua
Martin, Sherry A.
DIABETES, 2008, 57 : A564 - A564
[43] Hypoglycemia rates with titration of prandial premixed (ILPS/lispro) or basal bolus (glargine/lispro) insulin therapy in patients with type 2 diabetes (T2D)
Ahmann, Andrew
Jiang, Honghua
Martin, Sherry A.
DIABETES, 2008, 57 : A146 - A146
[44] Gene Expression and Metformin Efficacy in Type 2 Diabetes (T2D)
Prudente, Sabrina
Masotti, Andrea
Copetti, Massimiliano
Caporarello, Nunzia
Proto, Vittoria
Da Sacco, Letizia
Morini, Eleonora
Mercuri, Luana
Bailetti, Diego
Palena, Antonio
Baratta, Roberto
De Cosmo, Salvatore
Pellegrini, Fabio
Ludovico, Ornella
Frittitta, Lucia
Trischitta, Vincenzo
DIABETES, 2013, 62 : A430 - A430
[45] Long-Term Efficacy and Safety of Linagliptin in a Japanese Population with Type 2 Diabetes Aged ≥ 60 Years Treated with Basal Insulin: A Randomised Trial
Araki, Eiichi
Unno, Yuriko
Tanaka, Yuko
Sakamoto, Wataru
Miyamoto, Yuki
ADVANCES IN THERAPY, 2019, 36 (10) : 2697 - 2711
[46] Glycaemic efficacy and safety of linagliptin compared to basal bolus insulin regimen in non-cardiac surgical patients with type 2 diabetes: Linagliptin-Surgery trial
Umpierrez, G.
Vellanki, P.
Rasouli, N.
Baldwin, D.
Alexanian, S.
Anzola, I.
Urrutia, M.
Gomez, P.
Cardona, S.
Wang, H.
Pasquel, F.
DIABETOLOGIA, 2018, 61 : S377 - S378
[47] Open questions on basal insulin therapy in T2D: a Delphi consensus
Board, Delphi
Buzzetti, Raffaella
Candido, Riccardo
Esposito, Katherine
Giaccari, Andrea
Mannucci, Edoardo
Nicolucci, Antonio
Russo, Giuseppina T.
ACTA DIABETOLOGICA, 2024, : 1267 - 1281
[48] Advancing Therapy in Uncontrolled Basal Insulin (BI)-Treated Type 2 Diabetes (T2D): Subanalysis of the SoliMix Trial Outside Europe
Fonseca, Vivian
Rosenstock, Julio
Cheng, Alice Y.
Emral, Rifat
Sauque-Reyna, Leobardo
Mohan, Viswanathan
Al Sifri, Saud N.
Alvarez, Agustina
Djaballah, Khier
Picard, Pascaline
Souhami, Elisabeth
Mccrimmon, Rory J.
DIABETES, 2021, 70
[49] Advancing Therapy in Uncontrolled Basal Insulin (BI)-Treated Type 2 Diabetes (T2D): Subanalysis of the SoliMix Trial in Participants in Europe
Cheng, Alice Y.
Mccrimmon, Rory J.
Fonseca, Vivian
Trescoli, Carlos
Haluzik, Martin
Seufert, Jochen
Alvarez, Agustina
Souhami, Elisabeth
Picard, Pascaline
Bonnemaire, Mireille
Rosenstock, Julio
DIABETES, 2021, 70
[50] Long-Term Efficacy and Safety of Linagliptin in a Japanese Population with Type 2 Diabetes Aged ≥ 60 Years Treated with Basal Insulin: A Randomised Trial
Eiichi Araki
Yuriko Unno
Yuko Tanaka
Wataru Sakamoto
Yuki Miyamoto
Advances in Therapy, 2019, 36 : 2697 - 2711

← 1 2 3 4 5 →